
Keywords: Nasal polyposis; mepolizumab; IL-5; eosinophil; chronic rhinosinusitis; AE; Adverse event; ECG; Electrocardiography; EQ-5D; EuroQual 5-Dimensions; FVC; Forced vital capacity; ITT; Intent-to-treat; PEFR; Peak expiratory flow rate; PK; Pharmacokinetics; PnI